Showing 1651-1660 of 3315 results for "".
Qualities a Surgeon Seeks in an OD
https://modernod.com/topics/business/qualities-a-surgeon-seeks-in-an-od/39153/What exactly are ophthalmologists looking for when hiring an optometrist?From MD to OD: Tips for Referring Refractive Patients
https://modernod.com/topics/cataractrefractive-surgery/from-md-to-od-tips-for-referring-refractive-patients/39152/A surgeon suggests some advice for ODs based on his perspective.In Search of the Perfect Refractive Cataract Consult
https://modernod.com/topics/cataractrefractive-surgery/in-search-of-the-perfect-refractive-cataract-consult/39151/What it is and isn’t.Ten Do’s and Don’ts for Cataract Comanagement
https://modernod.com/topics/cataractrefractive-surgery/ten-dos-and-donts-for-cataract-comanagement/39136/The OD’s pocket guide to cataract comanagement.Be Ready When Asked, “What’s Your Specialty?”
https://modernod.com/topics/cataractrefractive-surgery/be-ready-when-asked-whats-your-specialty/39134/Trying to attract the attention of an ophthalmic practice? Specialization and passion top the list of attractive qualities.Achieving Durable Outcomes in Treatment-Naïve nAMD
https://modernod.com/specialty/retina/Achieving-Durable-Outcomes-in-treatment-naive-nAMD-2506/33189/Drs. Garg and Wykoff discuss a treatment-naïve patient with neovascular age-related macular degeneration and the impact of second-generation agents.Retina Specialist Perspectives
https://modernod.com/specialty/retina/Retina-Specialist-Perspectives-2506/33191/Retina specialists share collaborative care strategies to achieve the best outcomes for patients with retinal disease. <- Large Employers are Eyeing On-Site COVID-19 Vaccines, Survey Showshttps://modernod.com/news/large-employers-are-eyeing-on-site-covid-19-vaccines-survey-shows/2479044/Many large employers are expecting to offer COVID-19 vaccines on-site for workers by the end of the year, a new survey shows, according to a Fierce Healthcare
- BioTime Further Expands OpRegen Clinical Trial in Dry AMD With the Opening of Two Additional US Siteshttps://modernod.com/news/biotime-further-expands-opregen-clinical-trial-in-dry-amd-with-the-opening-of-two-additional-us-sites/2480141/BioTime announced the expansion of its ongoing phase 1/2a clinical trial for OpRegen, with the addition of two new U.S. sites that are expected to begin treating patients later this quarter. “The addition of these two leading U.S. clinical trial sites is in addition to our current two site
- Haag-Streit Opens New Surgical Microscope Production Site in Aesch, Switzerlandhttps://modernod.com/news/haag-streit-opens-new-surgical-microscope-production-site-in-aesch-switzerland/2481047/Haag-Streit announced the opening of a new state-of-the-art microscope production site in Aesch, Switzerland. In September 2021, Haag-Streit decided to reposition and focus solely on ophthalmology and the production and future development of the